<DOC>
	<DOCNO>NCT00768911</DOCNO>
	<brief_summary>Rationale : In light demonstrate activity anti-angiogenesis agent rGBM , reasonable postulate add agent standard RT chemotherapy up-front management newly diagnose GBM may improve clinical benefit . This study examine safety tolerability add CT-322 standard radiation therapy/temozolomide ( RT/TMZ ) backbone treatment newly diagnose GBM</brief_summary>
	<brief_title>CT-322 Combination With Radiation Therapy Temozolomide Treat Newly Diagnosed Glioblastoma Multiforme</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Informed consent 18 year old Newly diagnose , histologically confirm GBM ( grade IV astrocytoma ) : Subjects eligible original histology lower grade glioma subsequent histological diagnosis GBM make Central independent pathology confirmation GBM , concurrent subject enrollment Subjects sufficient biopsy material available perform PCR analysis MGMT promoter methylation must tissue submit designated laboratory analysis . Subjects insufficient tissue indeterminate result remain eligible enrollment . KPS ≥ 60 Be able begin treatment RT/TMZ within 6 week biopsy craniotomy satisfactory wound heal prior initiate treatment CT322 Be able undergo serial MRIs : Measurable assessable disease may may present CT scanning may substitute MRI scan Have adequate bone marrow , liver , renal , metabolic function assess follow : Hemoglobin ≥ 10.0 g/dL ( unsupported ) Absolute neutrophil count ( ANC ) ≥ 1,500/mm3 ( unsupported ) Platelet count ≥ 100,000/mm3 ( unsupported ) Total bilirubin ≤ 1.5 x ULN , unless due Gilbert 's disease ALT AST ≤ 3 x ULN INR &lt; 1.5 PT within normal limit ; PTT within normal limit Serum creatinine ≤ 1.5 x ULN Urine protein/creatinine ratio ( UPCR ) &lt; 1.0 Serum amylase lipase ≤ 1.5 x ULN 2dimensional echo MUGA scan LVEF within institutional normal range Stable decrease dose corticosteroid least 1 week prior screen MRI Contraceptive measure male female participant duration treatment 4 week follow discontinuation study treatment : Female subject reproductive potential must negative serum pregnancy test within 72 hour first administration CT322 Be able comply schedule visit , treatment plan , laboratory test , study procedure include receive daily external beam RT radiation treatment facility : integral affiliate investigative site treat radiation therapist participate study investigator ; agree follow radiation treatment guidance complete radiation treatment data collection form Prior CT322 therapy prior therapy another VEGFmodulating agent ( market investigational ) malignant glioma History hypersensitivity TMZ excipients , Dacarbazine ( DTIC ) Prior treatment GBM , except surgical resection and/or corticosteroid therapy Prior radiotherapeutic , local ( intratumoral ) systemic medical therapy ( include limit : chemotherapy , hormonal therapy , immunotherapy , antiangiogenic therapy , implantable Gliadel® wafer , molecularly target therapy ) brain tumor Current enrollment another therapeutic clinical trial involve ongoing therapy Concurrent severe and/or uncontrolled medical disease could compromise participation study : Pleural pericardial effusion ≥ grade 2 Uncontrolled diabetes , despite optimal medical management , accord opinion investigator Uncontrolled hypertension ( define systolic blood pressure &gt; 150 mmHg diastolic pressure &gt; 90 mmHg , despite optimal medical management ) Any active craniotomyrelated wound infection Active clinically significant infection ( &gt; grade 2 National Cancer Institute ( NCI ) Common Terminology Criteria Adverse Events v3.0 ( CTCAE ) require use antimicrobial agent , would otherwise , opinion investigator , interfere ability subject participate History clinically significant bleed diathesis coagulopathy include platelet function disorder ( e.g. , know hemophilia von Willebrand disease ) acquire bleed disorder within one year ( e.g. , acquire antifactor VIII antibody ) Ongoing recent ( ≤ 3 month ) significant gastrointestinal bleeding untreated recur Untreated peptic ulcer disease peptic ulcer disease treat &lt; 3 month Nonhealing wound ( include craniotomy wound ) , ulcer , bone fracture ; Glomerulonephritis proteinwasting glomerulopathy Within 12 month enrollment : Thrombotic embolic cerebrovascular accident transient ischemic attack CNS bleed ( stable , grade 1 ) Intraocular bleed , medical condition , opinion investigator increase risk intraocular bleeding Septic endocarditis ( unless deem cured antibiotic therapy least 3 month ) Coronary artery bypass graft , angioplasty , vascular stenting , myocardial infarction , unstable angina ; Symptomatic congestive heart failure ( New York Heart Association ≥ class II ) Any intraparenchymal CNS hemorrhage time enrollment except : Grade 1 intraparenchymal hemorrhage immediate postoperative period , Grade 1 intraparenchymal hemorrhage stable ( significant change 2 consecutive MRI scan least 4 week apart ) improved Subjects history prior cardiotoxic chemotherapy exposure subject thoracic irradiation involve cardiac tissue Other , nonglioma related major surgery , open biopsy , significant traumatic injury within 4 week first dose CT322 Placement subcutaneous indwell venous access port within 2 week first dose CT322 Known human immunodeficiency virus infection know active acute chronic viral hepatitis Prior malignancy within previous 3 year , except adequately treat basal cell skin cancer cervical carcinoma situ ; primary malignancy currently clinically significant require active intervention Has severe , acute , chronic medical psychiatric condition , laboratory abnormality could increase risk associate study participation study drug administration could interfere interpretation study result , judgment investigator , would make subject inappropriate entry study noncompliant studyrelated procedure Subjects medical condition would permit , judgment investigator , safe discontinuation medication prohibit throughout course study Any condition require therapeutic anticoagulation either oral ( e.g. , warfarin type ) injectable anticoagulant ; however , lowdose ( i.e. , 1 mg daily [ QD ] ) warfarin permit venous port patency maintenance Females pregnant breast feeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>glioblastoma</keyword>
	<keyword>Glioblastoma multiforme ( newly diagnose )</keyword>
</DOC>